However, oncogenic gene sets resulting from differential expression and/or mutations on KRAS or TP53 that are the most frequent in lung cancer cells9 were not constitutively enriched with our six DEG sets (Supplementary Data 4). This evidence concerns the gene KRAS and lung carcinoma.